OptimizeRx Corp. (NASDAQ:OPRX) Stock Rated “Moderate Buy” by Sell-Side Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has earned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.57.

OPRX has been the subject of a number of recent research reports. Wall Street Zen lowered shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Stifel Nicolaus set a $12.00 price target on shares of OptimizeRx in a research report on Thursday, August 13th. B. Riley Financial boosted their price target on shares of OptimizeRx from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 29th. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a report on Friday, August 14th. Finally, Weiss Ratings raised shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $9.37 on Thursday. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $22.25. The firm has a market capitalization of $176.53 million, a PE ratio of 40.74 and a beta of 1.26. The firm has a fifty day simple moving average of $8.08 and a two-hundred day simple moving average of $6.70.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a return on equity of 9.44% and a net margin of 4.66%. The company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. Analysts forecast that OptimizeRx will post 0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in OptimizeRx by 633.2% in the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock worth $1,362,000 after purchasing an additional 187,278 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of OptimizeRx in the first quarter worth $1,185,000. AWM Investment Company Inc. purchased a new position in shares of OptimizeRx during the 2nd quarter valued at $1,375,000. Dimensional Fund Advisors LP increased its stake in OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after buying an additional 102,661 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of OptimizeRx in the second quarter valued at about $370,000. 76.47% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation is a digital health company that provides technology and communication solutions for the life sciences and healthcare industries. Its platform connects pharmaceutical and biotechnology companies with healthcare providers and patients through digital channels integrated into electronic health records, electronic prescribing systems and other clinical workflows.

The company’s solutions support activities such as delivering treatment information, patient savings and affordability offers, medication adherence programs, and other communications intended to help patients access and remain on prescribed therapies.